Zimbabwe has turned down a major US healthcare agreement worth $367m (272 million pounds) over five years because of the United States' request for confidential biological samples.
The decision came to light after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson has since clarified that the United States was requesting health data for research and profit but was not willing to guarantee the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued talks to secure a agreement suitable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Implications
This development follows a comparable situation in Kenya, where a high court blocked a related health funding agreement after legal challenges were raised about the security of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance openness and responsibility.
Based on statements, 16 African countries have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any certainty that the end products would be accessible to our people if a future health crisis emerge."
National Interest and Global Health
He also noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting frameworks already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This system is intended to guarantee that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how future co-operation might be designed in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
Medical experts stated it recognised the government's concerns, but recommended that negotiations should continue considering a large portion of the country's Aids initiatives depended on international support.
"In cases where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
This impasse emphasises the ongoing challenges between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.